Sandoz represented by Pavia e Ansaldo obtains nullity of Astrazeneca’s patent for antipsychotic Quetiapine SR QUETIAPINE SR

Milan, 3 June 2015 – Pavia e Ansaldo represented Sandoz, the generic pharmaceuticals division of Novartis and one of the global leaders in the field, in the proceedings concerning AstraZeneca’s patent for the sustained release version of quetiapine, a blockbuster antipsychotic medicine whose worldwide market exceeds the value of 1 Billion Euro.

The Court of Turin by its decision dated June 1, 2015, declared that the Italian portion of AstraZeneca’s European Patent EP0907364 is null and void. A Panel of Judges, sustaining Sandoz’s legal arguments, rejected the technical expert’s opinion issued during the proceedings that had considered the patent to be valid.

This decision is the first on the merits in Italy and it is placed in the context of global litigation involving numerous jurisdictions such as UK, Germany, Netherlands, Spain, Belgium, Finland and Czech Republic.

Sandoz was represented by Pavia e Ansaldo with partner Gian Paolo Di Santo, head of Industrial and Intellectual Property department and associate Gabriele Girardello, who coordinated their activity with Sandoz global legal team.

Dragotti & Associati, patent attorneys, provided technical assistance with partner Mr. Roberto Pistolesi. Prof. Achille Patrizio Caputi of the Messina University acted as pharmacology expert.